- Iclusig EMA risk investigation results expected May 2014 provide short term catalysts for traders.
- Expansion into an additional 16 European countries & Australia + possible Japanese approval expected 2015.
- Analysts projected Iclusig sales upwards of $400 Million in the U.S. alone by 2019.
- Iclusig alternative applications provides possible supplemental revenue.
- AP26113, "mystery" drug and re-acquisition of Ridaforolimus from Merck provide further potential revenue.